Novo Nordisk is gaining ground on Eli Lilly in the obesity drug market despite a 12.6% quarterly and 15% yearly drop in Ozempic sales to DKK 27.83 billion in Q1. The recent FDA approval of Wegovy HD, which matches Eli Lilly's Zepbound in weight-loss efficacy, and promising clinical data on new drugs UBT251 and zenagamtide, enhance Novo Nordisk's investment appeal. This suggests potential growth opportunities despite current challenges in their insulin franchise and Ozempic demand decline.
The European Commission has approved Novo Nordisk's Wegovy pill, the first oral GLP-1 receptor agonist for weight management across the EU. This approval covers adults with obesity or overweight with related health issues and follows positive clinica...
The global blood glucose monitoring system market, valued at $16.8 billion in 2025, is projected to grow to $39.4 billion by 2035 at an 8.9% CAGR. Growth is fueled by rising diabetes prevalence, advancements in AI-enabled monitoring devices, and incr...
Vivani Medical is developing a semaglutide implant aimed at improving long-term adherence to GLP-1 treatments like Wegovy and Ozempic, which help with obesity and diabetes. The implant, designed to be replaced biannually or annually, could reduce sid...
